October 1, 2022

Two ambulatory infusion centers, Houston Methodist Baytown Hospital (Baytown) and Houston Methodist West Hospital (West), implemented the multidisciplinary program in 2020. The study continued through October 2021.

Updated guidelines recommend all patients with colorectal cancer, regardless of age or family history, should receive multigene panel testing.

Many studies’ results have suggested that the use of ctDNA for monitoring responses to treatment could be a significant tool for clinical research as well as a predictive biomarker.

As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

Prior to the 20th Annual Winter Lung Cancer Conference, Mark A. Socinski, MD, spoke with Targeted Therapies in Oncology about expectations for the upcoming meeting and major topics in non–small cell lung cancer.

Identifying a number of cancer predisposition genes could help improve upon risk assessment and counseling for ductal carcinoma in situ and contralateral breast cancer.

Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.

The phase 1b Study 116/KEYNOTE-524 trial of lenvatinib and pembrolizumab revealed the RAS gene signature to possibly be associated with progression-free survival in unresectable hepatocellular carcinoma.

Despite advances in the treatment of breast cancer, challenges remain, such as the development of resistance to existing therapies, serious adverse events, and suboptimal treatment adherence.

Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.